Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest
Clinical trials sponsored by Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest, explained in plain language.
-
New Two-Pronged attack on tough bile duct cancer
Disease control Recruiting nowThis study is testing a two-part treatment for advanced bile duct cancer that cannot be removed by surgery. It combines a heat-based procedure (radiofrequency ablation) applied inside the bile duct with a drug (durvalumab) given by IV. The goal is to see if this combination can h…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 03, 2026 21:40 UTC
-
Can a simple shunt help liver cancer patients live longer?
Disease control Recruiting nowThis study is observing whether adding a TIPS procedure—a small shunt placed in the liver to reduce pressure—helps patients with advanced liver cancer better tolerate their standard immunotherapy drugs (atezolizumab and bevacizumab). Researchers will follow 350 patients in German…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 03, 2026 21:40 UTC
-
New immune therapy trial targets Tough-to-Treat skin cancer
Disease control Recruiting nowThis study is testing whether the immunotherapy drug cemiplimab can help control advanced basal cell carcinoma when used as the first treatment. The trial will enroll about 34 adults with locally advanced skin cancer that cannot be treated with surgery or radiation. Participants …
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New combo attack on tough liver tumors
Disease control Recruiting nowThis study is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a targeted internal radiation treatment (Y-90 SIRT) is safe and effective for people with intermediate-stage liver cancer that cannot be removed by surgery. The goal is to see if th…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New Two-Drug attack on tough colon cancer shows promise in trial
Disease control Recruiting nowThis study is testing whether combining the drugs fruquintinib and tislelizumab works better than standard therapy for people with a common, hard-to-treat type of advanced colorectal cancer that hasn't spread to the liver. About 140 participants will be randomly assigned to recei…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug aims to keep aggressive bile duct cancer at bay after treatment
Disease control Recruiting nowThis study is testing whether a drug called ivosidenib can help prevent cancer from returning in people with a specific type of bile duct cancer who have already had surgery and chemotherapy. The trial will involve about 40 patients who have a particular genetic mutation (IDH1) i…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New combo therapy tested to boost stomach cancer fight before surgery
Disease control Recruiting nowThis early-stage trial is testing whether combining a newer immunotherapy drug (tislelizumab) with standard chemotherapy (FLOT) is safe and tolerable when given before surgery for certain stomach and esophagus cancers. The goal is to see if giving more chemotherapy before surgery…
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for stomach cancer: testing powerful drug duos before surgery
Disease control Recruiting nowThis study is testing whether new combinations of cancer drugs are safe and effective when given before surgery for a specific type of advanced stomach or esophageal cancer. The trial will involve about 36 patients whose cancer has a specific marker called HER2-positive. The goal…
Phase: PHASE1, PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New Triple-Threat therapy tested for aggressive stomach cancers
Disease control Recruiting nowThis study is testing a new three-drug combination for people with advanced stomach or esophageal cancer that has spread. It's for patients who have not yet received treatment for their advanced cancer and whose tumors test positive for two specific markers (HER2 and PD-L1). The …
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New Triple-Threat attack on advanced bowel cancer enters testing
Disease control Recruiting nowThis trial is testing a new three-part treatment for people with advanced colorectal cancer that cannot be surgically removed. It combines a standard chemotherapy, an immunotherapy drug (tislelizumab), and an experimental targeted drug (futibatinib). The main goal is to see how w…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New drug duo targets Tough-to-Treat penile cancer
Disease control Recruiting nowThis study is testing a new combination of two existing drugs, enfortumab vedotin and avelumab, as a first treatment for men with advanced penile cancer that has spread or cannot be removed by surgery. The main goal is to see how well the combination shrinks tumors and controls t…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
Massive 9,000-Patient study aims to map rare cancer landscape
Knowledge-focused Recruiting nowThis study is creating a large national registry to collect information about sarcoma, a rare type of cancer, and related tumors in Germany. It aims to enroll up to 9,000 adult patients to better understand how these cancers are currently treated and what outcomes patients experi…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:26 UTC